We are committed to transparency. Averitas believes in openly sharing information and soliciting patient and physician feedback on our products and therapeutic aims. It is this transparency and engagement that we hope lead to greater efficiency and efficacy in delivering meaningful therapies to patients.

Our company was formed in 2018, as the US commercial subsidiary of The Grünenthal Group. Grünenthal is a multinational pharmaceutical company headquartered in Germany, with a presence in more than 30 countries across Europe, Latin America, and the USA. For more than 70 years, Grünenthal has been a global leader in the research and development of therapeutics for pain, gout, and inflammation. Now, Averitas becomes a new chapter in the company’s global growth.